Navigation Links
Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
Date:10/1/2013

THOUSAND OAKS, Calif., Oct. 1, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) for $125 per share in cash. As announced on Aug. 25, the purchase price is $9.7 billion net of estimated Onyx cash. The tender offer expired at 12:00 midnight New York City time on Oct. 1, 2013. Amgen expects to complete the acquisition of Onyx later today through a merger under Section 251(h) of the General Corporation Law of the State of Delaware.

"Amgen's acquisition of Onyx fits perfectly with our commitment to advancing medicines for cancer patients around the world," said Robert A. Bradway, chairman and chief executive officer of Amgen.  "We look forward to working together with the talented staff at Onyx to make the most of our exciting oncology portfolio and pipeline."

As of the expiration of the tender offer, approximately 57,698,132 shares were validly tendered and not withdrawn in the tender offer, representing approximately 78.5 percent of Onyx's outstanding shares, according to the depositary for the tender offer. The condition to the tender offer that a majority of Onyx's outstanding shares on a fully-diluted basis be validly tendered and not withdrawn has been satisfied. As a result, Amgen has accepted for payment and will promptly pay for all validly tendered shares.

As a result of the merger planned to be effected later today, all remaining eligible Onyx shares will be converted into the right to receive $125 per share in cash, without interest and less any applicable withholding taxes,
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgens Acquisition of Onyx
2. Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil
3. Amgen To Participate At Citis 8th Annual Biotech Conference
4. Healthcare Briefing - Leading Medical Companies in the News: Bio-Solutions, Catalyst Pharmaceutical, MannKind, Amgen, Accuray
5. Amgen to Highlight New Data at Upcoming ESC Congress 2013
6. Acquisition of Onyx Pharmaceuticals, Inc. by Amgen Inc. May Not Be in the Best Interests of Onyx Pharmaceuticals, Inc. Shareholders
7. Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash
8. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
9. Amgens Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89
10. Amgen Announces Webcast of 2013 Second Quarter Financial Results
11. Amgen Award For Science Teaching Excellence Honors Outstanding Teachers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ... added to the Russell 1000 Index, effective June 26, ... the large-cap segment of the U.S. equity universe. It ... includes approximately 1000 of the largest securities based on ... membership. "We are pleased to be added ...
(Date:6/29/2015)... Axxess , an industry leader in ... vendor accredited by the American Nursing Credentialing Center – ... agencies select the right revenue cycle management (RCM) system ... business. Research by American Health Information Management ... a decrease in productivity of 54.4 - 69 percent ...
(Date:6/29/2015)... 29, 2015  Arbor Solution has added another ... high-powered, multi-functional M2150 offers two platforms: ... Core i5-4402E 1.6 GHz processor and i5-4422E ... and computing performance. Integrated Intel® HD Graphics 4600 ... suited for graphics-intense applications in operating rooms, clinical ...
Breaking Medicine Technology:ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Axxess Releases eGuide for Home Health Agencies, Revenue Cycle Management: What You Must Do Now - to Succeed! 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... N.J., July 05, 2007 /PRNewswire/ -- Results ... open-label, Phase,3 study showed that 77 percent ... 600 mg tablets with,100 mg ritonavir (PREZISTA/r) ... of antiretroviral (ARV) agents, reached a,plasma viral ...
... 2007 - ZIOPHARM,Oncology, Inc. (NASDAQ: ZIOP) announces ... II trial of ZIO-201 (isophosphoramide mustard,- IPM) ... at the,European Society of Medical Oncology (ESMO) ... The abstract entitled, "Phase-I/II,Study of IPM (ZIO-201) ...
Cached Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3
(Date:6/29/2015)... ... June 29, 2015 , ... Scientists from the Icahn School ... complete genomes by combining high-throughput DNA sequencing with genome mapping. The methodology enabled ... with human disease, but previously difficult to detect. The study was published today ...
(Date:6/29/2015)... Fernando Valley, CA (PRWEB) , ... June 29, 2015 , ... ... non-invasive treatments designed to lift and tighten sagging skin. Ulthera is a special treatment ... surgery. Instead, it uses ultrasound technology to gently stimulate collagen production. Ulthera is highly ...
(Date:6/29/2015)... ... June 29, 2015 , ... The ... Chemical Technology of The Hong Kong Polytechnic University (PolyU) has developed a new ... of edible oils has been a long-term issue in food safety, and becomes ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... company serving the Twin Cities area, provides money-saving tactics during a season of ... Twin Cities’ residents, addressing water conservation and other economical practices. , According to ...
(Date:6/29/2015)... ... , ... BaliniSports has been announced as an official sponsor and apparel provider ... This year’s contestants will be wearing pieces from the BaliniSports collection during practice sessions ... on to represent the state in the Miss Teen USA competition. , “BaliniSports ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 2Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 4Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 2Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 3Health News:PolyU develops a new method for rapid authentication of edible oils and screening of gutter oils 2Health News:Save Energy: MSP Plumbing, Heating & Air Endorses Efficiency 2Health News:Save Energy: MSP Plumbing, Heating & Air Endorses Efficiency 3Health News:BaliniSports Announced as Sponsor of the Miss Teen Nevada 2016 Competition 2
... study, published online in the Journal of Allergy ... therapies against childhood eczema in attempt to reduce the ... conducted by the University of Melbourne, Monash University and ... 8500 people who are part of the Tasmanian Longitudinal ...
... Dental researchers at the University of Washington have reported ... treated with the topical syrup xylitol, a naturally occurring ... General Session of the International Association for Dental Research. ... of the Marshall Islands, children 6 to 15 months ...
... mechanism present early in life predisposes people to worry, ... The brains of people who suffer from anxiety and ... show signs of being anxious even in situations considered ... Wisconsin School of Medicine and Public Health. , ...
... or tooth decay, continues to be the most prevalent ... and socio-economic consequences. It leads to the loss of ... necrosis of the subjacent dental pulp. In the U.S. ... with failure rates of up to 60%. Hence, there ...
... July 4 /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited (NYSE: ... of medical devices worldwide, today announced it has ... audited financial statements for,the fiscal year ended December ... (the "SEC") in accordance with United States,requirements. Mindray,s ...
... July 3 The July 5 issue of ... of Istanbul,on Organ Trafficking and Transplant Tourism, an ... May 2, 2008, at an,International Summit of more ... scholars from 78 countries and 20,international organizations. A ...
Cached Medicine News:Health News:Anxiety, Shyness May Be Long-Lasting Traits 2Health News:Novel hydrogel systems for dentin regeneration 2Health News:Mindray Announces 20-F Filing 2Health News:Commentary in The Lancet on the Declaration of Istanbul Sees Organ Transplantation Worldwide Threatened by Organ Trafficking and Transplant Tourism and Commercialism 2
Nordan tying forceps, straight, titanium, 6.5 mm tying platforms....
Harms-Tuebingen tying forceps, straight, 6 mm tying platforms....
Castroviejo straight tying forceps, straight shafts, 5 mm tying platforms, wide handle....
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Medicine Products: